New Treatment Strategy for Bladder Cancer Using EO9
Author Information
Author(s): Choudry G A, Stewart P A, Hamilton, Double J A, Krul M R L, Naylor B, Flannigan G M, Shah T K, Brown J E, Phillips R M
Primary Institution: Cancer Research Unit, Department of Pharmaceutical Chemistry, University of Bradford
Hypothesis
Do bladder tumors have elevated levels of the enzyme NQO1 that can activate EO9?
Conclusion
The study found that some bladder cancer patients have tumors with high levels of NQO1, which could allow for effective treatment with EO9.
Supporting Evidence
- EO9 showed good preclinical activity but failed in clinical trials due to rapid elimination from the body.
- Intravesical administration of EO9 could improve drug delivery to bladder tumors.
- Elevated NQO1 levels were found in a subset of human bladder tumors.
Takeaway
Some bladder cancer patients have a special enzyme that can help a drug called EO9 work better, especially if given in a certain way.
Methodology
The study measured NQO1 levels in bladder tumor tissue using immunohistochemical and enzymatic assays.
Limitations
The study primarily focuses on preclinical findings and may not fully translate to clinical efficacy.
Participant Demographics
The study mentions a subset of bladder cancer patients but does not provide specific demographic details.
Digital Object Identifier (DOI)
Want to read the original?
Access the complete publication on the publisher's website